The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC).
Antoinette J. Wozniak
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
James Moon
No relevant relationships to disclose
Charles R. Thomas
No relevant relationships to disclose
Karen Kelly
Consultant or Advisory Role - Genentech
Philip C. Mack
No relevant relationships to disclose
Laurie E. Gaspar
No relevant relationships to disclose
David Raben
No relevant relationships to disclose
Kishan J. Pandya
No relevant relationships to disclose
David R. Gandara
Consultant or Advisory Role - Genentech
Research Funding - Genentech